Literature DB >> 24133585

Small interfering RNA survivin and GRIM-19 co-expression salmonella plasmid inhibited the growth of laryngeal cancer cells in vitro and in vivo.

Lian-Ji Wen1, Li-Fang Gao, Chun-Shun Jin, He-Jia Zhang, Kun Ji, Jing-Pu Yang, Xue-Jian Zhao, Ming-Ji Wen, Guo-Fang Guan.   

Abstract

OBJECTIVE: To investigate the inhibitory effect of plasmid-based survivin-specific short hairpin RNA and GRIM-19 on the growth of Hep-2 laryngeal cancer cells.
METHODS: The plasmid expressing survivin-specific short hairpin RNA (shRNA) and GRIM-19 (p-siRNA survivin/GRIM-19) was prepared and transfected into Hep-2 cells with Lipofectamine 2000. The mRNA and protein expression of surviving and GRIM-19 were measured with RT-PCR and western blot assay, respectively. MTT assay was employed to detect the proliferation of Hep-2 cells, and flow cytometry and AO/EB assay were done to determine the apoptosis of Hep-2 cells.
RESULTS: In the p-siRNA survivin/GRIM-19, the mRNA and protein expression of survivin was markedly reduced by 54.4% and 42.2%, and the reduction in protein expression of surviving was more obvious than that in the p-siRNA survivin group (37%) (P<0.05). The protein expression of GRIM-19 was markedly enhanced when compared with the control group (P<0.01). MTT assay revealed the proliferation of Hep-2 cells undergoing transfection with p-siRNA survivin/GRIM-19 was markedly inhibited, and the inhibition rate was as high as 79%, which was higher than that in the psi-survivin group (45%) and p-GRIM-19 group (35%). AO/EB assay and flow cytometry indicated that the apoptotic cells in the p-siRNA survivin/GRIM-19 group were dramatically increased as compared to the psi-survivin group and p-GRIM-19 group.
CONCLUSION: The p-siRNA survivin/GRIM-19 has marked decrease in survivin expression and dramatic increase in GRIM-19 expression. Moreover, silencing of survivin and over-expression of GRIM-19 can significantly inhibit the growth and induce the apoptosis of Hep-2 in vitro and in vivo.

Entities:  

Keywords:  Co-expression plasmid; gene silencing; laryngeal cancer; survivin

Mesh:

Substances:

Year:  2013        PMID: 24133585      PMCID: PMC3796229     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  22 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Coordinated regulation of life and death by RB.

Authors:  B Nelson Chau; Jean Y J Wang
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

3.  Survivin antisense oligodeoxynucleotide inhibits growth of gastric cancer cells.

Authors:  Jian-Hui Yang; Yi-Chu Zhang; Hui-Qing Qian
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

4.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.

Authors:  G Ambrosini; C Adida; D C Altieri
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

Review 5.  Survivin as a target for new anticancer interventions.

Authors:  Nadia Zaffaroni; Marzia Pennati; Maria Grazia Daidone
Journal:  J Cell Mol Med       Date:  2005 Apr-Jun       Impact factor: 5.310

6.  GRIM-19-mediated translocation of STAT3 to mitochondria is necessary for TNF-induced necroptosis.

Authors:  Nataly Shulga; John G Pastorino
Journal:  J Cell Sci       Date:  2012-03-05       Impact factor: 5.285

Review 7.  Targeting the STAT pathway in head and neck cancer: recent advances and future prospects.

Authors:  N G Nikitakis; H Siavash; J J Sauk
Journal:  Curr Cancer Drug Targets       Date:  2004-12       Impact factor: 3.428

8.  Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck.

Authors:  Sichuan Xi; Qing Zhang; Kevin F Dyer; Edwina C Lerner; Thomas E Smithgall; William E Gooding; Joanne Kamens; Jennifer Rubin Grandis
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

Review 9.  Tumor-specific gene delivery using genetically engineered bacteria.

Authors:  J Theys; S Barbé; W Landuyt; S Nuyts; L Van Mellaert; B Wouters; J Anné; P Lambin
Journal:  Curr Gene Ther       Date:  2003-06       Impact factor: 4.391

Review 10.  Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.

Authors:  Patrick Chène
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

View more
  5 in total

1.  microRNA-423-3p promotes tumor progression via modulation of AdipoR2 in laryngeal carcinoma.

Authors:  Guofang Guan; Dejun Zhang; Ying Zheng; Lianji Wen; Duojiao Yu; Yanqing Lu; Yan Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 2.  GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism.

Authors:  Shreeram C Nallar; Dhan V Kalvakolanu
Journal:  Cytokine Growth Factor Rev       Date:  2016-09-15       Impact factor: 7.638

Review 3.  Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma.

Authors:  Zakir Khan; Abdul Arif Khan; Hariom Yadav; Godavarthi B K S Prasad; Prakash Singh Bisen
Journal:  Cell Mol Biol Lett       Date:  2017-04-05       Impact factor: 5.787

Review 4.  Targeting Programmed Fusobacterium nucleatum Fap2 for Colorectal Cancer Therapy.

Authors:  Kumar Ganesan; Songhe Guo; Sundaz Fayyaz; Ge Zhang; Baojun Xu
Journal:  Cancers (Basel)       Date:  2019-10-18       Impact factor: 6.639

Review 5.  Recombinant Attenuated Salmonella enterica as a Delivery System of Heterologous Molecules in Cancer Therapy.

Authors:  Elayne Irene Becerra-Báez; Sergio Enrique Meza-Toledo; Paola Muñoz-López; Luis Fernando Flores-Martínez; Karla Fraga-Pérez; Kevin Jorge Magaño-Bocanegra; Uriel Juárez-Hernández; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.